CC-486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC-486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). After a pharmacokinetic assessment period, 31 patients (MDS n = 18, CMML n = 4, and AML n = 9) entered a clinical phase in which they received CC-486 300 mg once-daily for 21 days of repeated 28-day cycles. Red blood cell transfusion independence rates in the MDS/CMML and AML subgroups were 33% and 25%, respectively, and 2 MDS/CMML patients attained hematologic improvement as a best response on-study. No baseline gene mutation was predictive of response/nonresponse. CC-486 allows flexible dosing and schedules to improve tolerability or response. Neutropenia in early treatment cycles deserves scrutiny and may warrant initiation of prophylactic antibiotics.
| INTRODUCTION
Azacitidine is an epigenetic modifier and DNA methyltransferase inhibitor (DNMTi). [1] [2] [3] Hypermethylation of epigenetic regions of DNA and consequent alterations in expression of genes associated with normal cell cycling, apoptosis, and tumor suppression, are implicated in the pathogenesis of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). 4 Azacitidine mechanisms of action have not been fully elucidated, but it is thought to reduce DNA methylation upon incorporation into DNA, alter protein expression upon incorporation into RNA, and exert direct cytotoxic effects on abnormal hematopoietic cells in bone marrow. [1] [2] [3] Parenteral azacitidine has been extensively evaluated in patients with MDS, chronic myelomonocytic leukemia (CMML), and AML in large randomized clinical trials, [5] [6] [7] in regional registry studies, [8] [9] [10] [11] [12] [13] and in numerous smaller retrospective analyses of patients treated in community practice. 14, 15 These studies show azacitidine reduces cytopenias in select lower-risk MDS and prolongs overall survival (OS) in higher-risk MDS and AML, [5] [6] [7] 16 may be effective maintenance therapy after induction chemotherapy (IC) or allogeneic hematopoietic stem cell transplant (alloHSCT), [17] [18] [19] [20] and can induce responses in patients with relapsed/refractory disease. 12, 21 Importantly, the study of azacitidine has revealed nuances of treatment with DNMTi therapy not seen with the use of traditional chemotherapy. These include improved OS, which can occur in the absence of a complete remission (CR), 7, 8, 22 a need to treat with as many as 6 treatment cycles prior to achieving maximal response, and hematologic toxicities seen during early treatment tend to decrease if patients can remain on treatment. 7, 8, 23 CC-486 is an oral formulation of azacitidine in clinical development for treatment of hematological malignancies. A phase 1 dose-escalation study evaluated treatment outcomes for patients with MDS, CMML, or AML who, after receiving an initial cycle of standard subcutaneous (SC) azacitidine dosing (75 mg/m 2 /day for 7 days of a 28-day cycle), received CC-486 doses of 180-600 mg/day for 7 consecutive days per cycle thereafter. 24 Pharmacodynamic evaluation of 7-day administration of SC azacitidine and oral CC-486 showed both treatments resulted in greatest respective reductions in global methylation (per Infinium Human Methylation27 BeadArray assay; Illumina, San Diego, CA) near mid-cycle, after which, methylation levels began to rise to approximately pretreatment levels. 24, 25 As some of the benefit of parenteral azacitidine is thought to be from global hypomethylation, it is reasonable to consider that prolongation of hypomethylation may be beneficial. This is logistically difficult for parenteral administration, and one potential advantage of an oral formulation of azacitidine is that it may be administered more easily over a prolonged period. Indeed, extending dosing of CC-486 to 14 or 21 days per 28-day cycle was shown to significantly reduce methylation of highly methylated gene loci from pretreatment levels and hypomethylation was sustained over the entire treatment cycle. 25, 26 Moreover, sustained hypomethylation with CC-486 can be achieved with lower azacitidine exposure. 26 Cumulative azacitidine exposures per cycle with 300 mg daily 14-and 
| Analysis populations
The safety evaluable population included patients who received at least 1 dose of CC-486, and the efficacy evaluable population comprised patients who received at least 1 dose of CC-486 and who had at least 1 post-baseline efficacy assessment performed in the clinical phase of the study.
| Endpoints
The primary goal was to evaluate the safety and tolerability of 
Months since diagnosis, median (range) 15.9 (−0.4, 118.1) 13.5 (2.5, 26.8)
Prior injectable DNMTi use, n (%) 6 (33) 2 (50) 6 (67) 14 ( 
| Mutational analyses
The Illumina TruSight Myeloid Panel (Illumina, San Diego, CA) was used to identify mutations in the coding region of 54 relevant genes involved in AML and MDS (Supporting Information Table S1 ). The assay targets 15 full exomes and exonic hotspots in 39 additional genes. Sequencing data (500× coverage per sample) were obtained on the Illumina MiSeq genome sequencing platform. Variant allele frequencies were calculated as a fraction of the mutated allele reads over total reads (mutated allele + wild type allele) in each sample.
| Statistical analysis
Demographic, safety, efficacy, and mutational outcomes are reported descriptively.
3 | RESULTS
| Patient disposition
The study was conducted between February 9, 2012 and May 12, 2015. Of 36 patients screened, 31 patients received CC-486
during the clinical phase of the study and comprise the safety and efficacy cohort for these analyses (Supporting Information Figure S1 ). In total 18 patients (58%) had a diagnosis of MDS, 4 patients (13%) had CMML, and 9 patients (29%) had AML ( Table 1 ). The most common reasons for study discontinuation
were TEAEs (n = 12, 36%) and disease progression (n = 11, 36%) (Supporting Information Figure S1 ). dose reductions from 300 to 200 mg QD (1 patient subsequently returned to the 300 mg QD dose).
| Safety
The most common TEAEs were gastrointestinal (84%) and hematologic (81%) in nature, with the majority of events occurring during the first 2 treatment cycles ( Table 3 ). The most frequent TEAEs (any cause) were diarrhea (61%), and anemia, neutropenia, and nausea (45% each) (Supporting Information Table S2 ). Except for fatigue, all treatment-related TEAEs occurring in ≥10% of patients, at any point within the study, were gastrointestinal or hematological (Table 4 ).
Seven grade 3 gastrointestinal TEAEs were reported in 6 patients (19%) ( Table 5) ; no grade 4 gastrointestinal TEAEs occurred on-study.
Grade 3-4 hematologic TEAEs were reported for 19 patients, including 10 patients who experienced grade 4 neutropenia (Table 5) .
Treatment-related grade 3-4 TEAEs were reported for 20 patients (65%; MDS n = 14, CMML n = 1, AML n = 5); those occurring in 2 or more patients were neutropenia (n = 11), anemia (n = 5), thrombocytopenia (n = 4), febrile neutropenia (n = 4), and pneumonia (n = 3). All treatment-related grade 4 TEAEs reported on-study were hematological.
A total of 13 CC-486-related serious TEAEs were reported for 9 patients (29%): febrile neutropenia (n = 4), pneumonia (n = 3), and (n = 1 each) hemolytic anemia, atrial fibrillation, supraventricular tachycardia, upper gastrointestinal hemorrhage, peritonsillar abscess, and septic shock.
Dose modifications due to gastrointestinal TEAEs were reported for 5 patients (16%) or due to hematologic TEAEs for 6 patients (19%) ( Table 2 ). Three patients (10%) experienced 1 or more TEAE that led to CC-486 dose reduction (neutropenia, nausea and vomiting, and WBC decrease). CC-486 dose interruptions were reported for 11 patients (36%). TEAEs leading to discontinuation of CC-486 (n = 10, 32.3%) were thrombocytopenia and fatigue (n = 2 each), febrile neutropenia, disseminated intravascular coagulation, diarrhea, pneumonia, sepsis, and decreased appetite (n = 1 each).
Six patients died during the clinical phase of the study or within 28 days after their last CC-486 dose; 2 of the deaths were considered possibly related to study drug (septic shock, hemolytic anemia).
| Efficacy
ORR for patients with MDS and CMML was 32%, including 4 patients who attained CR and 3 patients who had PR (Table 6) The safety profile of CC-486 300 mg QD for 21 days per 28-day cycle is consistent with the known safety profile of injectable azacitidine. 35 The proportions of patients with anemia, neutropenia, and thrombocytopenia in the current study were 45%, 45%, and 32%, respectively. Comparably, cytopenias were reported for 51%, 66%, and 70%, respectively, in patients with higher-risk MDS receiving parenteral azacitidine in the phase 3 AZA-001 trial. 35 It is possible that lower azacitidine exposure over a longer period with CC-486 may attenuate druginduced cytopenias often seen during early treatment. Gastrointestinal side effects appear to be more common with the oral formulation than the injectable formulation of azacitidine. For example, proportions of patients experiencing diarrhea or vomiting in this study (61% and 39%, respectively) are higher than those reported for patients in the AZA-001 trial (22% and 27%). 35 It is unclear if this is a function of changes in the microbiome in the gut leading to gastrointestinal AEs, 36 or, perhaps the local effects of oral cytotoxic therapy which may cause irritation to the gastrointestinal mucosa.
As reported for SC azacitidine, 35 ; the effect of CC-486 on OS
has not yet been reported and was not captured in this phase 1 study, 
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